David Bellovin

David Bellovin is currently the Vice President, Discovery and Translational Biology at Attovia Therapeutics. Prior to this role, David held various positions at Alamar Biosciences, Inc., Zai Lab, and Five Prime Therapeutics, Inc., focusing on oncology discovery, in vivo pharmacology, and anti-cancer therapeutics. Their extensive experience includes working at Stanford University School of Medicine as an Instructor and Postdoctoral Fellow, where David researched liver cancer metastasis and developed novel mouse models. David has a Ph.D. in Experimental Pathology/Cancer Biology from Harvard Medical School and B.S. in Biochemistry, Molecular and Cellular Biology from the University of Arizona.